Tests JNJ-89402638 alone and with other drugs in advanced colorectal and stomach cancers
Tests a new drug, JNJ-89402638, in adults with advanced colorectal or stomach cancer.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Seoul, South KoreaSee the 2 sitesAlso in 2 other countries, 10 sites
- Trial code
- Registry title
- A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 260 people, planned
- Started
- 15 Oct 2024
- Expected to end
- 19 Jul 2028
- Type of study
- Interventional, 6 groups
- Treatments tested
- JNJ-89402638
- Bevacizumab
- FOLFOX
- FOLFIRI
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colorectal cancer or gastric/gastroesophageal junction cancer that has spread and got worse after standard treatment.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Colorectal adenocarcinoma that has spread or cannot be removed by surgery, worsening after 2 or more prior lines of standard therapy. Some groups need microsatellite stable (MSS) or proficient mismatch repair (pMMR) cancer after 1 prior line. One group is for gastric or gastroesophageal junction adenocarcinoma worsening after 1 or more prior lines. Disease must be measurable or evaluable by RECIST 1.1; Part 2 needs at least 1 measurable lesion.
- Earlier treatment
- Standard treatment must have been tried first (2 or more prior lines for most colorectal groups). One group needs a prior fluoropyrimidine and irinotecan doublet such as FOLFIRI. Another group must not have had irinotecan before for metastatic disease.
- Biomarker or test result
- Two combination groups need MSS or pMMR colorectal cancer.
Main reasons for not taking part
- Active brain metastases, leptomeningeal disease, or untreated spinal cord compression
- Side effects from earlier cancer treatment not yet improved to Grade 1 or lower (some exceptions)
- Another cancer, unless it is unlikely to affect the study results
- Glucocorticoids above 10 mg/day prednisone or equivalent within 7 days before the first dose
- Live attenuated vaccine within 4 weeks before or after study treatment
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- For Part 1 (dose escalation), Part 2 (Arm A [JNJ-89402638 monotherapy]): Have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma (CRC) progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting; For Part 2 Arm B (JNJ-89402638 + bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of CRC progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting; For Part 2 Arm C (JNJ-89402638 + FOLFOX/bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC progressing after 1 or more prior lines of standard therapy in the metastatic/unresectable setting. Participants must have previously received a fluoropyrimidine and irinotecan doublet (such as FOLFIRI); For Part 2 Arm D (JNJ-89402638 + FOLFIRI/bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of MSS or pMMR CRC progressing after 1 prior line of standard therapy in the metastatic/unresectable setting. Must not have received irinotecan previously for metastatic disease; For Part 2 Arm E (JNJ-89402638 monotherapy in mGAC): Have histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressing after 1 or more prior lines of standard therapy in the metastatic/unresectable setting
- Have evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) version 1.1; Part 1: Must have either measurable or evaluable disease; Part 2: Must have at least 1 measurable lesion
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Have an estimated or measured glomerular filtration rate (GFR) greater than or equal to (>=) 30 milliliter per minute (mL/min) based on modification of diet in renal disease (MDRD) 4-variable formula
Who cannot take part
- Toxicity from prior anticancer therapy that has not resolved to Grade less than or equal to (<=)1 (except alopecia, vitiligo, Grade <= 2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement). For Part 2 Arm C: Grade 2 or higher peripheral neuropathy is considered exclusionary
- Has a prior or concurrent second malignancy (other than the disease under study) unless natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Received glucocorticoids (doses >10 mg/day prednisone or equivalent) within 7 days prior to the first dose of study drug
- Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment or within 4 weeks after the last dose of study treatment
- Active (new or progressive) brain metastases, leptomeningeal disease, or untreated spinal cord compression
Where in South Korea
Also in 2 other countries, 10 sites
- Asan Medical CenterSeoul, South KoreaTaking people
- Severance Hospital, Yonsei University Health SystemSeoul, South KoreaTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
The 6 groups in the trial
- Part 1 (Dose Expansion)Treatment being tested
Participants with unresectable metastatic colorectal adenocarcinoma (mCRC) will receive JNJ-89402638 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially until the recommended Phase 2 Dose(s) (RP2D) and optimal route(s) of administration for JNJ-89402638 monotherapy have been identified.
Treatment: JNJ-89402638
- Part 2 (Dose Expansion): Arm ATreatment being tested
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) and route as determined in Part 1 as a monotherapy.
Treatment: JNJ-89402638
- Part 2 (Dose Expansion): Arm BTreatment being tested
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 along with bevacizumab or biosimilar.
Treatment: JNJ-89402638 and Bevacizumab
- Part 2 (Dose Expansion): Arm CTreatment being tested
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 along with bevacizumab or biosimilar and FOLFOX.
Treatment: JNJ-89402638, Bevacizumab, and FOLFOX
- Part 2 (Dose Expansion): Arm DTreatment being tested
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 in combination with bevacizumab or biosimilar and FOLFIRI.
Treatment: JNJ-89402638, Bevacizumab, and FOLFIRI
- Part 2 (Dose Expansion): Arm ETreatment being tested
Participants with metastatic gastric adenocarcinoma (mGAC) will receive JNJ-89402638 at the RP2D(s) and route as determined in Part 1.
Treatment: JNJ-89402638
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies
- Plain-language title
- Tests JNJ-89402638 alone and with other drugs in advanced colorectal and stomach cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026